Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$10.85 +0.07 (+0.67%)
As of 08/7/2025 03:59 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$10.81
$10.89
50-Day Range
$9.23
$10.85
52-Week Range
$8.37
$13.14
Volume
119,722 shs
Average Volume
224,101 shs
Market Capitalization
N/A
P/E Ratio
36.17
Dividend Yield
3.23%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

A cyclist rides past outside the Beijing No
Chinese court sentences a Japanese man to more than 3 years in prison on espionage charges
A Japanese man has been sentenced to three and a half years in prison in China on espionage charges...
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
ALPMY Astellas Pharma Inc. - Seeking Alpha
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 at the beginning of the year. Since then, ALPMY shares have increased by 12.3% and is now trading at $10.85.

Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its quarterly earnings data on Wednesday, July, 30th. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.26. The firm earned $3.41 billion during the quarter, compared to analysts' expectations of $3.20 billion. Astellas Pharma had a net margin of 4.34% and a trailing twelve-month return on equity of 19.76%.

Astellas Pharma's stock split on Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/30/2025
Today
8/07/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CIK
1446390
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
36.17
Forward P/E Ratio
25.83
P/E Growth
N/A
Net Income
$334.93 million
Net Margins
4.34%
Pretax Margin
1.63%
Return on Equity
19.76%
Return on Assets
8.75%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
1.13
Quick Ratio
0.85

Sales & Book Value

Annual Sales
$12.56 billion
Price / Sales
N/A
Cash Flow
$1.83 per share
Price / Cash Flow
5.94
Book Value
$5.52 per share
Price / Book
1.97

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.26

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners